The Combined Use of CPIB and Thyroxine in Treatment of Hyperlipoproteinemias
The combined effect of CPIB and levothyroxine on lipoprotein concentrations in 13 patients with various types of hyperlipoproteinemias has been investigated. Analysis of long-term observations indicates the following: (1) CPIB lowers Sf 20-105 concentrations profoundly regardless of the initial lipoprotein distribution. (2) Addition of levothyroxine to CPIB produces no further significant effect on Sf 20-105 concentrations. (3) The effect of CPIB on Sf 0-20 concentrations appears to depend on the initial lipoprotein distribution. In carbohydrate-sensitive hyperlipemias CPIB can markedly increase Sf 0-20 levels, whereas it has no such effect in other hyperlipoproteinemias. On occasion, a marked Sf 0-20 lowering effect occurs in patients with Sf 0-20 hyperlipoproteinemias. Two such instances are reported in detail. (4) In combined Sf 0-20 and Sf 20-105 hyperlipoproteinemias the combination of CPIB and thyroxine is often more effective than either agent used separately in reducing total lipoprotein concentrations.
- © 1966 American Heart Association, Inc.